Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | |||
---|---|---|---|---|---|---|
Aktuell sind keine Nachrichten verfügbar, die den gewählten Kriterien entsprechen. |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MPH HEALTH CARE | 21,000 | +1,94 % | EQS-News: MPH Health Care AG verkauft 1,5 Mio. Aktien ihrer Beteiligung M1 Kliniken AG an deren Vorstände | EQS-News: MPH Health Care AG
/ Schlagwort(e): Beteiligung/Unternehmensbeteiligung
MPH Health Care AG verkauft 1,5 Mio. Aktien ihrer Beteiligung M1 Kliniken AG an deren Vorstände... ► Artikel lesen | |
EYEPOINT PHARMACEUTICALS | 15,310 | -0,58 % | Veru, EyePoint Pharmaceuticals, SINTX Technologies among healthcare movers | ||
AMARIN | 0,820 | -0,61 % | Amarin Corporation plc: Amarin Announces Results of Annual General Meeting of Shareholders |
DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced shareholder approval of all proposed resolutions specified at its 2024... ► Artikel lesen | |
SELLAS LIFE SCIENCES | 1,418 | -1,12 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update | Announced Phase 2a study of SLS009 in r/r AML Showing 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeding the Targeted 20% and 100% Response Rate in Patients with Identified Biomarkers... ► Artikel lesen | |
MADRIGAL PHARMACEUTICALS | 187,60 | -1,83 % | Madrigal Pharmaceuticals, Inc.: Madrigal Statement on the Passing of Dr. Stephen Harrison | ||
CATALYST PHARMACEUTICALS | 13,855 | -1,98 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024 | ||
ANI PHARMACEUTICALS | 61,00 | 0,00 % | Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts | ||
TITAN PHARMACEUTICALS | 6,440 | -100,00 % | Titan Pharmaceuticals, Inc.: Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria | SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that by letter dated January 24, 2024, the Company... ► Artikel lesen | |
ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information | Conference Call Scheduled for Thursday, February 15 at 11:30 AM ESTNORTHVALE, NJ / ACCESSWIRE / February 14, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCBB:ELTP), a specialty pharmaceutical... ► Artikel lesen | |
CANNABIS SATIVA | - | - | Cannabis Sativa, Inc.: PrestoDoctor Expands Its Cannabis Telemedicine Service to West Virginia | MESQUITE, NV / ACCESSWIRE / January 17, 2024 / Cannabis Sativa, Inc. (OTCQB:CBDS) announces that PrestoDoctor - the #1 patient-rated medical cannabis telemedicine service - now offers its online medical... ► Artikel lesen | |
BLUM HOLDINGS | - | - | Blum Holdings: Blüm Holdings Releases 2023 Annual Report: Executive Summary | ||
BMP PHARMA TRADING | 4,800 | 0,00 % | PTA-News: B.M.P. Pharma Trading AG: BMP erzielt operatives Rekordjahresergebnis im abgelaufenen Geschäftsjahr 2023 - Wachstumskurs wird fortgesetzt - Ertragsbudget für 2024 auf stabilen Niveau | DJ PTA-News: B.M.P. Pharma Trading AG: BMP erzielt operatives Rekordjahresergebnis im abgelaufenen Geschäftsjahr 2023 - Wachstumskurs wird fortgesetzt - Ertragsbudget für 2024 auf stabilen Niveau
... ► Artikel lesen | |
THERIVA BIOLOGICS | 0,345 | +1,03 % | Theriva Biologics, Inc.: Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma | -Phase 1 trial in collaboration with Sant Joan de Déu-Barcelona Children's Hospital (SJD) determined to have a positive outcome by the study Monitoring Committee-
-Safety and clinical outcomes support... ► Artikel lesen | |
KAZIA THERAPEUTICS | 0,389 | 0,00 % | KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer | ||
ALLERGY THERAPEUTICS | 0,037 | +23,73 % | XFRA HHU: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |